Market Cap 9.36B
Revenue (ttm) 634.44M
Net Income (ttm) -25.51M
EPS (ttm) N/A
PE Ratio 99.75
Forward PE 99.54
Profit Margin -4.02%
Debt to Equity Ratio 0.00
Volume 232,500
Avg Vol 858,414
Day's Range N/A - N/A
Shares Out 56.29M
Stochastic %K 82%
Beta 1.11
Analysts Strong Sell
Price Target $188.00

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale co...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 781 250 0111
Fax: 781 250 0115
Address:
Building 1, Suite 100 41 Seyon Street, Waltham, United States
ortega1963
ortega1963 Dec. 22 at 4:11 PM
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:07 PM
$RGEN long 166
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:32 PM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $157.72, with a low RSI of 22.33 indicating oversold conditions. This suggests potential for a rebound. The stock is near its 60D low of $121.18, providing a strong support level. Directional Bias: The RSI indicates that the stock is oversold, while the MA30 (158.59) and MA50 (156.17) suggest a potential reversal. Given the proximity to the 60D low, there is a bullish bias for a short-term recovery. Suggested Trade Plan: - Entry: $157.72 - Stop Loss: $153.00 (approximately 3.5% below entry) - Take Profit Targets: 1. TP1: $162.00 (2.9% gain) 2. TP2: $168.00 (6.5% gain) 3. TP3: $184.00 (16.8% gain) With these targets, TP3 offers a potential ROI of over 17%. Monitor closely for price action around the targets. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:19 AM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $158.09, showing signs of potential reversal as indicated by an RSI of 33.28, suggesting it is oversold. The current price is above the 30-day MA of $158.01 and significantly above the 60-day low of $121.18, indicating a possible upward correction. Directional Bias: The RSI below 35 indicates bearish momentum, but the proximity to the 30-day MA and the historical high of $174.01 suggests potential for a bullish reversal. Trade Plan: - Suggested Entry: $158.50 (slightly above the last close) - Stop Loss: $154.00 (below the 30-day MA) - Take Profit Targets: 1. $165.00 (4.5% ROI) 2. $170.00 (7.5% ROI) 3. $185.00 (17% ROI) With the ATR at $4.76, the risk-to-reward ratio favors this setup. Monitor closely for price action around the entry point. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Mal1ah_Bowen
Mal1ah_Bowen Dec. 16 at 4:54 PM
$RGEN SBFM this one doesn’t need hype, it just needs attention
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 9:07 PM
Barclays has updated their rating for Repligen ( $RGEN ) to Overweight with a price target of 200.
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:29 PM
Wells Fargo updates rating for Repligen ( $RGEN ) to Overweight, target set at 175 → 190.
0 · Reply
Goldenpoint9
Goldenpoint9 Dec. 15 at 1:48 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:52 AM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $157.39, showing a neutral market sentiment with an RSI of 42.21, indicating potential for upward momentum as it is below the 50 threshold. The stock is near its 30-day moving average (MA30) of 157.6 and above the 50-day moving average (MA50) of 155.55, suggesting a possible bullish reversal. Directional Bias: Given the RSI and proximity to key MAs, there is a slight bullish bias. The recent price action is also within the 60-day high of 174.01 and low of 121.18, providing a clear range for potential movement. Trade Plan: - Suggested Entry: $158.00 - Stop Loss: $152.00 (approximately 3.5% risk) - Take Profit Targets: 1. $165.00 (4.4% gain) 2. $170.00 (7.9% gain) 3. $184.00 (16.8% gain) With these targets, we aim for at least a 17% ROI on the third target. Monitor price action closely. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:46 PM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $162.92, showing bullish momentum with an RSI of 62.06, indicating it is approaching overbought territory but still has room to run. The price is above the 30-day MA of $157.22 and the 50-day MA of $155.33, reinforcing a positive trend. Directional Bias: Given the current price relative to the moving averages and the 60-day high of $174.01, there is a bullish bias. The price is well above the recent lows, suggesting a solid upward trend. Trade Plan: - Suggested Entry: $163.50 - Stop Loss: $157.00 (approximately 4.5% below entry) - Take Profit Targets: - Target 1: $168.00 (2.3% gain) - Target 2: $172.00 (5.1% gain) - Target 3: $191.00 (17% gain) The strategy aims for a minimum 17% ROI on the third target while maintaining a manageable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Latest News on RGEN
Repligen: Rare Growth In The Biopharma Supplies Industry

Nov 14, 2025, 3:28 AM EST - 5 weeks ago

Repligen: Rare Growth In The Biopharma Supplies Industry


Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 5:01 PM EDT - 2 months ago

Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript


Repligen to Report Third Quarter 2025 Financial Results

Oct 15, 2025, 7:30 AM EDT - 2 months ago

Repligen to Report Third Quarter 2025 Financial Results


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 4 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA


Repligen Corporation: Still Navigating Through The Covid Cliff

Aug 14, 2025, 3:24 PM EDT - 4 months ago

Repligen Corporation: Still Navigating Through The Covid Cliff


Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Jul 31, 2025, 10:45 AM EDT - 5 months ago

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026


Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 5:31 PM EDT - 5 months ago

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript


Repligen to Report Second Quarter 2025 Financial Results

Jul 17, 2025, 7:30 AM EDT - 5 months ago

Repligen to Report Second Quarter 2025 Financial Results


Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 12:58 PM EDT - 8 months ago

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript


Repligen Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 8 months ago

Repligen Reports First Quarter 2025 Financial Results


Repligen: Ongoing Bioprocessing Market Recovery

Mar 20, 2025, 7:52 AM EDT - 9 months ago

Repligen: Ongoing Bioprocessing Market Recovery


Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:53 PM EST - 10 months ago

Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript


Repligen Launches the CTech™ SoloVPE® PLUS System

Jan 6, 2025, 7:30 AM EST - 1 year ago

Repligen Launches the CTech™ SoloVPE® PLUS System


Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:07 PM EST - 1 year ago

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript


Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 3:03 PM EDT - 1 year ago

Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript


Repligen Lowers Guidance On China Weakness, Analyst Expects

Jul 30, 2024, 12:01 PM EDT - 1 year ago

Repligen Lowers Guidance On China Weakness, Analyst Expects


ortega1963
ortega1963 Dec. 22 at 4:11 PM
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:07 PM
$RGEN long 166
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:32 PM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $157.72, with a low RSI of 22.33 indicating oversold conditions. This suggests potential for a rebound. The stock is near its 60D low of $121.18, providing a strong support level. Directional Bias: The RSI indicates that the stock is oversold, while the MA30 (158.59) and MA50 (156.17) suggest a potential reversal. Given the proximity to the 60D low, there is a bullish bias for a short-term recovery. Suggested Trade Plan: - Entry: $157.72 - Stop Loss: $153.00 (approximately 3.5% below entry) - Take Profit Targets: 1. TP1: $162.00 (2.9% gain) 2. TP2: $168.00 (6.5% gain) 3. TP3: $184.00 (16.8% gain) With these targets, TP3 offers a potential ROI of over 17%. Monitor closely for price action around the targets. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:19 AM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $158.09, showing signs of potential reversal as indicated by an RSI of 33.28, suggesting it is oversold. The current price is above the 30-day MA of $158.01 and significantly above the 60-day low of $121.18, indicating a possible upward correction. Directional Bias: The RSI below 35 indicates bearish momentum, but the proximity to the 30-day MA and the historical high of $174.01 suggests potential for a bullish reversal. Trade Plan: - Suggested Entry: $158.50 (slightly above the last close) - Stop Loss: $154.00 (below the 30-day MA) - Take Profit Targets: 1. $165.00 (4.5% ROI) 2. $170.00 (7.5% ROI) 3. $185.00 (17% ROI) With the ATR at $4.76, the risk-to-reward ratio favors this setup. Monitor closely for price action around the entry point. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Mal1ah_Bowen
Mal1ah_Bowen Dec. 16 at 4:54 PM
$RGEN SBFM this one doesn’t need hype, it just needs attention
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 9:07 PM
Barclays has updated their rating for Repligen ( $RGEN ) to Overweight with a price target of 200.
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:29 PM
Wells Fargo updates rating for Repligen ( $RGEN ) to Overweight, target set at 175 → 190.
0 · Reply
Goldenpoint9
Goldenpoint9 Dec. 15 at 1:48 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:52 AM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $157.39, showing a neutral market sentiment with an RSI of 42.21, indicating potential for upward momentum as it is below the 50 threshold. The stock is near its 30-day moving average (MA30) of 157.6 and above the 50-day moving average (MA50) of 155.55, suggesting a possible bullish reversal. Directional Bias: Given the RSI and proximity to key MAs, there is a slight bullish bias. The recent price action is also within the 60-day high of 174.01 and low of 121.18, providing a clear range for potential movement. Trade Plan: - Suggested Entry: $158.00 - Stop Loss: $152.00 (approximately 3.5% risk) - Take Profit Targets: 1. $165.00 (4.4% gain) 2. $170.00 (7.9% gain) 3. $184.00 (16.8% gain) With these targets, we aim for at least a 17% ROI on the third target. Monitor price action closely. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:46 PM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $162.92, showing bullish momentum with an RSI of 62.06, indicating it is approaching overbought territory but still has room to run. The price is above the 30-day MA of $157.22 and the 50-day MA of $155.33, reinforcing a positive trend. Directional Bias: Given the current price relative to the moving averages and the 60-day high of $174.01, there is a bullish bias. The price is well above the recent lows, suggesting a solid upward trend. Trade Plan: - Suggested Entry: $163.50 - Stop Loss: $157.00 (approximately 4.5% below entry) - Take Profit Targets: - Target 1: $168.00 (2.3% gain) - Target 2: $172.00 (5.1% gain) - Target 3: $191.00 (17% gain) The strategy aims for a minimum 17% ROI on the third target while maintaining a manageable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:49 AM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $160.67, showing strength with an RSI of 61.12, indicating bullish momentum but not overbought. The stock is above both the 30-day MA (156.33) and the 50-day MA (154.38), suggesting a positive trend. The 60-day high of $174.01 provides a potential resistance level. Directional Bias: Bullish. The current price is above key moving averages, and the RSI indicates room for further upside without being overextended. Trade Plan: - Suggested Entry: $161.00 - Stop Loss: $154.00 (4.3% below entry) - Take Profit Targets: 1. Target 1: $168.00 (4.3% gain) 2. Target 2: $172.00 (6.8% gain) 3. Target 3: $188.00 (16.5% gain) With a potential ROI of over 17% on Target 3, this trade offers a favorable risk-reward ratio. Monitor the price action closely and adjust stop loss accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:37 PM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $161.79, showing strong momentum with an RSI of 67.2, indicating it is nearing overbought conditions. However, the price remains above both the 30-day MA of $156.37 and the 50-day MA of $153.67, suggesting bullish sentiment in the short to medium term. Directional Bias: The recent high of $174.01 indicates potential upward movement, while the 60-day low of $112.73 provides a solid support level. Given the current price and the proximity to the high, a cautious bullish approach is warranted. Trade Plan: - Suggested Entry: $162.50 - Stop Loss: $155.00 (4.7% below entry) - Take Profit Targets: 1. Target 1: $168.00 (3.1% gain) 2. Target 2: $172.00 (5.8% gain) 3. Target 3: $190.00 (16.8% gain) This plan offers a potential ROI of over 17% at the third target while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:37 AM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $165.76, near its 60-day high of $174.01. The RSI of 69.8 indicates an overbought condition, suggesting potential for a pullback or consolidation before further upward movement. The MA30 at $156.53 and MA50 at $152.08 show bullish momentum, indicating support levels. Directional Bias: While the RSI suggests caution, the strong support from moving averages indicates potential for upward movement. Given the proximity to the 60D high, a strategic entry could capitalize on a potential breakout. Trade Plan: - Suggested Entry: $165.76 - Stop Loss: $159.34 (below MA30) - Take Profit Targets: - Target 1: $172.00 (4% gain) - Target 2: $178.00 (7.4% gain) - Target 3: $194.00 (17% gain) This plan allows for a structured approach with a favorable risk-reward ratio. Monitor closely for market volatility. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:12 PM
Actionable Trade Alert for $RGEN: Market Context: $RGEN is currently trading at $165.76, near its 60-day high of $174.01. The RSI of 69.8 indicates an overbought condition, suggesting potential for a pullback or consolidation before further upward movement. The MA30 at $156.53 and MA50 at $152.08 show bullish momentum, indicating support levels. Directional Bias: While the RSI suggests caution, the strong support from moving averages indicates potential for upward movement. Given the proximity to the 60D high, a strategic entry could capitalize on a potential breakout. Trade Plan: - Suggested Entry: $165.76 - Stop Loss: $159.34 (below MA30) - Take Profit Targets: - Target 1: $172.00 (4% gain) - Target 2: $178.00 (7.4% gain) - Target 3: $194.00 (17% gain) This plan allows for a structured approach with a favorable risk-reward ratio. Monitor closely for market volatility. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 2:46 PM
$RGEN Current Stock Price: $163.60 Contracts to trade: $165 RGEN Dec 19 2025 Call Entry: $5.62 Exit: $9.99 ROI: 78% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Nov. 27 at 11:00 AM
Wall St is expecting 0.44 EPS for $RGEN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
c2rshi2r
c2rshi2r Nov. 26 at 7:50 PM
$RGEN https://www.marketbeat.com/instant-alerts/rep-lisa-c-mcclain-sells-repligen-corporation-nasdaqrgen-stock-2025-11-25/
0 · Reply
stockpicker63
stockpicker63 Nov. 21 at 3:25 PM
Watch today $RGEN, $VFC and $INTU
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 11:02 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 4:56 PM
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 4:55 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 29 at 7:29 PM
$QCOM $QBTX $RGEN $RGTU CYCLE TRADING SIGNAL PLUGGED INTO AI 🔥 LISTS 🔥
0 · Reply